The FDA is going forward with an investigation into the safety of the abortion pill mifepristone, an initiative which could ...

The drumbeat of news regarding Asian pharma—and particularly China—continues to grow louder. | The drumbeat of news regarding ...

With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic ...

In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia and Fierce Pharma’s Zoey Becker and Angus Liu ...

Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised ...

Medical device distribution giant Medline was slammed for a second time since April by an FDA warning letter that chided the ...

Eli Lilly and Boehringer Ingelheim are cutting back on planned investments in Germany in response to a new government ...

A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen ($949.37 million) loss for the fiscal year. Last month, a federal jury ...

With a new patent settlement, Axsome Therapeutics can lower its sword against prospective generics makers taking aim at its ...

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...

Nearly a decade later, taking the center stage at ASCO 2026, Akeso’s ivonescimab made history by offering the first-ever ...

Amid shifts in attitudes around family planning and contraception—and as the advent of telehealth outfits like Hims & Hers ...